# Opus Genetics, Inc. (IRD) · Edgar & Edgarette company card

> Opus Genetics (IRD) grew revenue 29.1% in FY2025 to $14 million, operating margin -272% against a -3.8% median for pharmaceutical preparations, equity 30.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1228627 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/IRD) · [JSON](https://www.pops4.com/boards/company/IRD.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $14M |
| Revenue growth, 1 year | 29.1% |
| Revenue growth per year | 121.6% |
| Operating margin | -271.9% (prior year -564.7%) |
| Net margin | -349.3% |
| Operating cash flow | −$35M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $45M |
| Long-term debt | $1M |
| Total assets | $50M |
| Total equity | $15M |
| Equity ÷ assets | 30.5% |
| Return on equity | -323.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -11.42 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -271.9% in FY2025; revenue is hard to predict: its 80% range is ±66%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $14.2M (FY2025), total debt $1.1M. Experience: revenue up 29.1% on the year, up 121.6% a year over 4 years; operating margin -271.9%, up from -564.7%. Soundness: equity 30.5% of assets, return on equity -323.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $6.3M and $31.0M next year (method v4.1: its own 3-year record of growth weighed at 40% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $5.7M to $34.6M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -271.9% against a -3.8% median; growth 29.1% against 13.7%.

Range logged 2026-09-29, receipt 46193aeb043d03c8, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-10-21 ([filing](https://www.sec.gov/Archives/edgar/data/1228627/000114036126040377/0001140361-26-040377-index.htm))

## Recent filings

- 8-K · filed 2026-10-21 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1228627/000114036126040377/0001140361-26-040377-index.htm)
- 8-K · filed 2026-10-15 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1228627/000114036126039781/0001140361-26-039781-index.htm)
- 8-K · filed 2026-09-11 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1228627/000114036126036277/0001140361-26-036277-index.htm)
- 8-K · filed 2026-09-09 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1228627/000114036126035979/0001140361-26-035979-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1228627/000162828026054381/0001628280-26-054381-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/0001628280-26-053824-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001228627.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1228627

## Cite

POPS4, Edgar & Edgarette: Opus Genetics, Inc. (IRD) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/IRD. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.